Infection prevention technology leader Nanosonics (ASX:NAN) has announced plans to commence an on-market share buyback of up to $20 million during the 2026 financial year, reflecting its strong balance sheet, consistent cash generation, and confidence in its long-term growth prospects.
The buy-back forms part of the company’s ongoing capital management strategy, balancing investment in innovation and expansion with the return of capital to shareholders.
Chief Executive Officer and President Michael Kavanagh said the decision underscored the company’s financial strength and its continued focus on strategic growth.
“Nanosonics’ business model is built on a solid foundation of capital revenue from trophon® device sales and growing recurring revenue from consumables and services,” he said.
“With no debt and a history of predictable cash flows, we’ve invested decisively in our next growth horizon through the development and launch of trophon3 and trophon2 Plus, and the FDA De Novo approval of our CORIS system. These innovations strengthen our leadership in infection prevention and open significant new opportunities for continued growth.”
Mr Kavanagh said the Board was confident the company had sufficient cash reserves to fund ongoing strategic initiatives, including the continued expansion of the trophon business, the commercial rollout of CORIS, and potential selective acquisitions. “The buy-back reflects that confidence and our commitment to delivering long-term value to shareholders,” he said.
Nanosonics said the buy-back would be conducted in the ordinary course of trading, outside designated blackout periods, and within the ‘10/12 limit’ permitted under the Corporations Act 2001. Shares purchased will be cancelled, reducing the total number on issue.